Mia is one of the world’s major infectious diseases. In 2017, an estimated 219 million cases and around 435,000 deaths resulted from mia. Most of the deaths occurred in children under five years old. Artemisinin is a key ingredient in first-line mia treatments recommended by the WHO. It is extracted from traditional Chinese medical herb Artemisia annua, but because it is extracted from plants, its supply can suffer from climatic variations, leading to unstable provision of antimial medicines and major price variations. See full list on The partnership aimed at developing a complementary, semisynthetic, source of artemisinin, to improve the availability of high-quality artemisinin derivatives to drug manufacturers and contribute to stabilizing the price of artemisinin-containing antimials to benefit patients and payers. The original idea and the proof of concept were developed at the University of California-Berkeley, the project was then managed by the Institute for One World Health (IOWH. From the proof of concept, a first chemical route was developed on a laboratory scale by Amyris Biotechnologies, a US based Biotech start-up. Sanofi was selected as the manufacturing partner, due to the mia program within its Access to Medicines department, and because of its production and technological competences and capa. Tll & Melinda Gates Foundation (BMGF) provided significant ficial suppption to its latest stages. The partnership w... See full list on At Sanofi, a tremendous amount of work was done to access a scalable and cost-effective process to convert biosynthetic artemisinic acid into artemisinin, scaling-up the process to industrial scale, and ensuring production up to the highest quality standards. A large number of Sanofi staff, primarily in France and in Italy, was involved in this project. See full list on
Get Price